Klin Farmakol Farm. 2026;40(1):19-24 | DOI: 10.36290/far.2026.011

Allergen immunotherapy for respiratory allergies

Jiří Nevrlka
Farmakologický ústav Lékařské fakulty Masarykovy univerzity, Brno
Oddělení klinické mikrobiologie a imunologie Fakultní nemocnice Brno-Bohunice
Klinika nemocí plicních a tuberkulózy, Fakultní nemocnice Brno-Bohunice
UPIRA, s. r. o., Brno

Specific allergen immunotherapy is the only causal and disease‑modifying treatment modality for respiratory allergies. It represents a personalized approach that may induce long‑term immunotolerance to causal allergens. It can thus reduce or even completely eliminate symptoms of allergic rhinitis and, in some patients, allergic asthma, decrease the need for pharmacotherapy, improve patients' quality of life and, last but not least, protect them against progression of the allergic disease. This review summarizes the mechanisms of action and clinical efficacy of allergen immunothe­rapy in diseases related to inhalant allergens and discusses indications and available therapeutic options in the Czech Republic.

Keywords: allergen immunotherapy, inhalant allergy, allergic rhinitis, allergic asthma.

Received: February 11, 2026; Revised: March 22, 2026; Accepted: March 28, 2026; Published: April 20, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nevrlka J. Allergen immunotherapy for respiratory allergies. Klin Farmakol Farm. 2026;40(1):19-24. doi: 10.36290/far.2026.011.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. EAACI. The European Academy of Allergy and Clinical Immunology Advocacy Manifesto [Internet]. EAACI; 2024 [cited 2026-01-06]. Available from: https://eaaci.org/wp-content/uploads/2024/02/EAACI_Advocacy_Manifesto.pdf.
    2. Muraro A, et al. Allergen Immunotherapy Guidelines Part 1: Systematic reviews. EAACI; 2017. ISBN 978-3-9524815-0-9.
    3. Rybníček O, Seberová E. Průvodce alergenovou imunoterapií: doporučení České společnosti alergologie a klinické imunologie ČLS JEP. Praha: Tigis; 2021.
    4. Muraro A, Roberts G. Allergen Immunotherapy Guidelines Part 2: Recommendations. EAACI; 2017. ISBN 978-3-9524815-1-6.
    5. Státní ústav pro kontrolu léčiv. Souhrny údajů o přípravku (SPC) registrovaných terapeutických alergenů [Internet]. Státní ústav pro kontrolu léčiv. [cited 2026-01-06]. Available from: https://www.sukl.cz.
    6. Passalacqua G. Sublingual immunotherapy: World Allergy Organization Position Paper 2014. World Allergy Organ J. 2014;7(1):21. Go to original source... Go to PubMed...
    7. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1):17. Go to original source...
    8. Viswanathan RK, Busse WW. Allergen Immunotherapy in Allergic Respiratory Diseases: From Mechanisms to Meta-analyses. Chest. 2012;141(5):1303-1314. Go to original source...
    9. Cappella A, Durham SR. Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother. 2012;8(10):1499-1512. Go to original source... Go to PubMed...
    10. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017 update [Internet]. Global Initiative for Asthma; 2017 [cited 2026-01-06]. Available from: https://ginasthma.org.
    11. Devillier P, Dreyfus JF, Demoly P, et al. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med. 2014;12:71. Go to original source...
    12. Nevrlka J. Hodnocení efektu alergenové imunoterapie v rámci léčby respiračních alergií. Vnitř Lék. 2025;71(7):468-472. Go to original source...
    13. Pfaar O, Demoly P, Gerth van Wijk R, et al; European Academy of Allergy and Clinical Immunology. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69(7):854-867. Go to original source...
    14. Kappen J, Diamant Z, Agache I, et al. Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper. Allergy. 2023;78(11):2835-2850. Go to original source...
    15. Gradman J, Halken S. Preventive Effect of Allergen Immunotherapy on Asthma and New Sensitizations. J Allergy Clin Immunol Pract. 2021;9(5):1813-1817. Go to original source... Go to PubMed...
    16. Asaria M, Dhami S, van Ree R, et al. Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview. Allergy. 2018;73(2):269-283. Go to original source...
    17. Klimek L, et al. ARIA guideline 2019: treatment of allergic rhinitis in the precision medicine era. Allergy. 2019;74(12): 2386-2398.
    18. Cirillo I, Marseglia G, Klersy C, et al. Allergic patients have more numerous and prolonged respiratory infections than nonallergic subjects. Allergy. 2007;62(9):1087-1090. Go to original source... Go to PubMed...
    19. Incorvaia C, Rapetti A, Scurati S, et al. Importance of patient's education in favouring compliance with sublingual immunotherapy. Allergy. 2010;65(10):1341-1342. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.